openPR Logo
Press release

Infectious Disease Therapeutics Market Is Thriving Worldwide with the outstanding players Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche AG

03-02-2019 08:28 AM CET | Health & Medicine

Press release from: Coherent Market Insights,Inc

Infectious Disease Therapeutics

Infectious Disease Therapeutics

Increasing advancements in rapid diagnosis of various infectious diseases allowing early and quicker diagnosis is greatly impacting the medical outcome of disease treatment. Advanced technologies such as lateral flow, agglutination assays, and solid phase that are used in rapid diagnostics of infectious diseases are integrated with innovative features such as portability of handheld devices, offering point-of-care treatment to the patients.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1658

Moreover, advancements in the technology of point-of care diagnostics is expected to drive growth of infectious disease therapeutic market over the forecast period. For instance, in 2014, Becton, Dickinson, and Company offered point-of-care system BD FACSPresto for HIV/AIDS. It offers percentage results of CD4 T lymphocytes and hemoglobin concentration. Moreover, in January 2017, Infectious Disease Research Institute (IDRI) developed a fusion antigen, which is used as a part of diagnostic test manufactured by InBios International, Inc. for Chagas disease.

Moreover, research funding is provided by various government and private organizations for infectious diseases to provide effective diagnostic and treatment options. For instance, in November 2016, QuantuMDx Group received funding from Bill & Melinda Gates Foundation to develop and test company’s CAPTURE-XT pathogen concentration technology and Q-POC molecular diagnostic platform for rapid low cost detection of tuberculosis. In January 2018, University of Glasgow-led project received US$ 1.85 million funding, which is a part of Global Challenges Research Fund (GCRF). This project will develop new tests for parasitic diseases and rapid testing in remote locations to help enable rapid diagnosis and rapid treatment of infectious diseases.

Asia Pacific is expected to witness fastest growth over the forecast period. Rising demand for efficient and quick diagnostic testing, increasing number of strategies adopted by market players to expand their geographical reach in this region, and engagement of government organizations in minimizing the disease burden are factors that are expected to drive market growth in Asia Pacific region.

For instance, in March 2013, Qiagen N.V. launched its careHPV test in China. CareHPV is a molecular diagnostic test designed to screen for high risk human papillomavirus (HPV) at low-resource settings such as areas lacking electricity, water or laboratories. Qiagen also gained the approval from China's State Food and Drug Administration (SFDA) for the careHPV in 2012. Moreover, in March 2018, Government of India launched the TB Free India Campaign with an aim to completely eliminate tuberculosis (TB) by 2025.

Key players operating in the infectious disease therapeutics market include Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Merck & Co., Inc., and Novartis International AG.

Get a sample copy of report @ https://www.coherentmarketinsights.com/insight/request-sample/1658

Key players are developing new products for the treatment of infectious diseases and are also receiving approvals to commercialize their products. For instance, in May 2017, Merck received FDA approval for its ISENTRESS HD, a new 1200 mg integrase inhibitor for HIV-1 infected patients. This drug can also be used in combination therapy with other antiretroviral.

Infectious Disease Therapeutics Market – Taxonomy

The global infectious disease therapeutics market is segmented on the basis of mode of treatment, drug class, disease infection, end user, and region as mentioned below:

By Mode of Treatment

Drugs
Oral Administration
Topical
Injections
Others
Vaccines
By Drug Class

Anti-Bacterial
Anti-Viral
Anti-Parasite
Anti-Fungal
Others
By Disease Indication

Tuberculosis
HIV/AIDS
Influenza
Hepatitis
Others
By End User

Hospital Pharmacy
Retail Pharmacy
Others
By Region

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Infectious Disease Therapeutics Market Is Thriving Worldwide with the outstanding players Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche AG here

News-ID: 1627771 • Views:

More Releases from Coherent Market Insights,Inc

Incredible Growth of +22.1% CAGR for Nanopharmaceuticals Market is Thriving Worldwide with Top Players Like Novartis AG, Pfizer, Inc., Hoffmann-La Roche AG, Sanofi S.A, Shire Plc., and Teva Pharmaceuticals Industries Limited, Novavax, Inc., Stryker Corpor
Incredible Growth of +22.1% CAGR for Nanopharmaceuticals Market is Thriving Worl …
Key players in the market are focused on research and development of nanopharmaceuticals in order to develop novel products to address the critical unmet needs of patients. According to the P&T Community Journal, December 2017, DTXSPL8783, dendrimer for cancer treatment is being investigated, which is in clinical trials of phase 1 study, for patients with advanced cancer. Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2485 Similarly, Vivagel developed by Starpharma, is in phase 3 clinical
Childhood Absence Epilepsy Treatment Market Growing at a CAGR of 5.4% by 2026, Focusing on top key players Pfizer, Inc., GlaxoSmithKline Plc, Insys Therapeutics, Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd
Childhood Absence Epilepsy Treatment Market Growing at a CAGR of 5.4% by 2026, F …
According to various studies published by the National Center for Biotechnology Information and recent recommendation by the National Institute for Health and Care Excellence (NICE), 2018, Ethosuximide should be considered as a first choice of treatment, followed by Valproate and Lamotrigine. Moreover, various manufacturers such as Insys Therapeutics (Cannabidiol) and Cavion, Inc. (CX-8998) have drugs in phase II stage in clinical trials and these therapies are expected to be launched
Pneumococcal Vaccines Market is anticipated to grow at a CAGR of 7.5% by 2026: Top key players Pfizer, Inc., Merck & Co. Inc., and GlaxoSmithKline plc
Pneumococcal Vaccines Market is anticipated to grow at a CAGR of 7.5% by 2026: T …
Healthcare facilities are looking forward to expand their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination For instance, in April 2016, Glaxo Smith Kline (GSK) and Vodafone collaborated to provide smartphones with an app to various healthcare facilities in northern Mozambique, Africa for a period of one year. The program received funds from GAVI and United States Agency for International Development (USAID) under
Ureteral Stents Market Global Outlook 2018-2026 | Leading Vendors Applied Medical, Allium Medical, Bard Medical, B.Braun, Boston Scientific, Cook Medical, Coloplast, Conmed Corporation, Optimed, Olympus America, Pnn Medical A/S, Taewoong Med
Ureteral Stents Market Global Outlook 2018-2026 | Leading Vendors Applied Medica …
New designs such as a helically-cut ureteral stent is aimed to stretch and conform the ureter. Drug-eluting stents with an antimicrobial property are designed to reduce bacterial adherence to ureteral stents. Furthermore, bioabsorbable stents are designed to reduce infection and prevent the forgotten stent syndrome. In June 2018, HydrUStent, a startup based at the University of Minho in Portugal, announced its research on developing a ureteral stent made from a

All 5 Releases


More Releases for Disease

Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research. Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight: Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and